NEW YORK, Oct. 24 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN - News) today announced an extensive program of clinical trials which will assess the safety and efficacy of multiple neurohormones used in combination to treat obesity. This integrated approach to obesity therapy is based on extensive clinical experience with the analog of the human hormone, amylin, called pramlintide, and preclinical data combining neurohormones. Results presented today from a Phase 2 extension study demonstrate that patients completing 52 weeks of pramlintide therapy experienced a 7-8% mean body weight reduction (depending upon dose) compared to a 1% reduction in patients receiving placebo. Also, preclinical data were presented revealing novel, additive and synergistic weight loss effects when amylin is used in combination with other neurohormones.
